PANTAX: a phase Ib clinical trial of the efflux pump inhibitor SCO-101 in combination with gemcitabine and nab-paclitaxel in non-resectable or metastatic pancreatic cancer.
Saved in:
| Title: | PANTAX: a phase Ib clinical trial of the efflux pump inhibitor SCO-101 in combination with gemcitabine and nab-paclitaxel in non-resectable or metastatic pancreatic cancer. |
|---|---|
| Authors: | Shim S; Department of Oncology, Clinical Cancer Research Center, Aalborg University Hospital, Hobrovej 18 - 22, 9000, Aalborg, Denmark.; Department of Clinical Medicine, Aalborg University, Aalborg, Denmark., Reinacher-Schick A; Dept. of Hematology, Oncology and Palliative Care, St. Josef-Hospital, Bochum, Germany., Kraeft AL; Dept. of Hematology, Oncology and Palliative Care, St. Josef-Hospital, Bochum, Germany., Per Pfeiffer; Department of Oncology, Odense University Hospital, Odense, Denmark.; University of Southern Denmark, Odense, Denmark., Tarpgaard LS; Department of Oncology, Odense University Hospital, Odense, Denmark.; University of Southern Denmark, Odense, Denmark., Ettrich TJ; Department of Internal Medicine I, University Hospital of Ulm - Oberer Eselsberg, Ulm, Germany., Kestler A; Department of Internal Medicine I, University Hospital of Ulm - Oberer Eselsberg, Ulm, Germany., Christensen S; Department of Oncology, Clinical Cancer Research Center, Aalborg University Hospital, Hobrovej 18 - 22, 9000, Aalborg, Denmark., Jandu H; Scandion Oncology A/S, Copenhagen, Denmark., Nawabi M; Scandion Oncology A/S, Copenhagen, Denmark., Roest NL; Scandion Oncology A/S, Copenhagen, Denmark., Damstrup L; Scandion Oncology A/S, Copenhagen, Denmark., Vestlev PM; Scandion Oncology A/S, Copenhagen, Denmark., Brünner N; Scandion Oncology A/S, Copenhagen, Denmark., Stenvang J; Scandion Oncology A/S, Copenhagen, Denmark., Ladekarl M; Department of Oncology, Clinical Cancer Research Center, Aalborg University Hospital, Hobrovej 18 - 22, 9000, Aalborg, Denmark. morten.ladekarl@rn.dk.; Department of Clinical Medicine, Aalborg University, Aalborg, Denmark. morten.ladekarl@rn.dk. |
| Source: | Investigational new drugs [Invest New Drugs] 2025 Apr; Vol. 43 (2), pp. 337-347. Date of Electronic Publication: 2025 Apr 24. |
| Publication Type: | Journal Article; Clinical Trial, Phase I; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Springer Country of Publication: United States NLM ID: 8309330 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1573-0646 (Electronic) Linking ISSN: 01676997 NLM ISO Abbreviation: Invest New Drugs Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1573-0646 |
|---|---|
| DOI: | 10.1007/s10637-025-01526-7 |
